AbCellera Biologics Stock Rises After Positive Data, Capital Raise
This news comes as the broader healthcare sector is experiencing a modest gain of 0.17%, contributing to the stock’s upward movement in a generally stable market environment.
On Wednesday, AbCellera Biologics commenced an underwritten public offering of $200 million of its common shares and pre-funded warrants.
AbCellera will use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes.
The trial results released on Tuesday indicate that ABCL635 has established a new efficacy benchmark for treating menopausal symptoms, which could position AbCellera favorably in the competitive healthcare landscape.
